SV Life Sciences said Monday that Darren Black was named a managing partner while Tom Flynn was made a partner. Black joined SV Life Sciences in 2003 and will continue to focus on healthcare services, pharmaceutical services and healthcare information technology. Flynn joined the life sciences VC firm in 2011 and targets post-acute care delivery and healthcare information technology services.
SV Life Sciences (“SVLS”), a leading international life sciences venture capital firm, today announced the appointments of Darren Black as Managing Partner and Tom Flynn as Partner.
“It is with great enthusiasm that we recognize both Darren and Tom for their extraordinary accomplishments and significant contributions to SVLS’ success,” said Eugene Hill, Managing Partner and head of SVLS’ Healthcare Services team. “These promotions are also an opportunity for the firm to demonstrate an ongoing commitment to offering long-term career growth and opportunities for advancement to its investment professionals. I look forward to Darren’s and Tom’s continued success, as they take on these enhanced roles within the firm.”
Mr. Black, who joined SVLS in 2003, was named a Partner in 2008. As a Managing Partner, he will continue to focus on his areas of expertise, healthcare services, pharmaceutical services and healthcare information technology. Prior to joining SVLS, Mr. Black was a Co-Founder and President of ClinCare, a site management organization; and PharmaStar, a central nervous system education services company. Darren earned an MBA from the Wharton School at the University of Pennsylvania and an AB in Government from Harvard College.
Mr. Flynn joined SVLS in 2011 as a Venture Partner and is focused on investments in the areas of post-acute care delivery and healthcare information technology services. Before joining SVLS, Mr. Flynn served as a Partner at healthcare-focused growth capital investor Ferrer Freeman & Co., where he focused on investing activities, including deal origination and structuring, fundraising and portfolio management. He also served as the Firm’s Chief Financial Officer. Earlier in his career, Mr. Flynn served in a variety of important roles at GE Capital, Prudential Capital Corporation and Lehman Brothers, focused in the areas of private equity, fixed income and mezzanine debt portfolio management and investment banking. Mr. Flynn earned an MBA from Harvard Business School and an AB Degree in Economics from Holy Cross College.
Messrs. Black and Flynn are members of SVLS’ team of 35 professionals organized according to experience and specialization into three practice areas: Biotechnology / Biopharmaceuticals; Medical Devices / Instrumentation; and Healthcare Services / Healthcare Information Technology. These individuals’ diverse and complimentary skill sets and experiences enable SVLS to tailor an investment team for almost any life science business. Typically, SVLS recruits operating executives who have distinguished careers in the life sciences fields and can bring extensive operating expertise to the SVLS portfolio of investments. They assist in sourcing, building and exiting investments successfully. SVLS employs a close symbiosis between operating and financial professionals which has led to significant success over five investment funds.
About SV Life Sciences
SV Life Sciences is a leading international life sciences venture capital firm. SVLS affiliated funds have been investing in life sciences companies since the early 1980s and the firm closed its first dedicated life sciences fund in 1994. The SVLS team manages five venture capital funds. The Firm employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and healthcare services / healthcare information technology. SVLS has offices in Boston, London and San Francisco. For more information, please visit the company’s website at http://www.svlsa.com.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.